Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-dose and Randomized, Single-center, Placebo- and Active-controlled, Crossover Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Subjects

Next Previous
Search
Trial Profile

Single-dose and Randomized, Single-center, Placebo- and Active-controlled, Crossover Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omecamtiv mecarbil (Primary) ; Moxifloxacin
  • Indications Acute heart failure; Chronic heart failure; Heart failure
  • Focus Adverse reactions
  • Sponsors Cytokinetics

    • Most Recent Events

    • 17 Sep 2021 Results of primary analysis assessing effect of therapeutic concentrations of OM on electrocardiogram parameters presented at the 2021 American College of Clinical Pharmacology Annual Meeting
    • 16 Jun 2021 Results evaluating the effect of therapeutic concentrations of Omecamtiv Mecarbil on electrocardiogram parameters, published in the British Journal of Clinical Pharmacology
    • 06 Mar 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top